Jaw osteonecrosis (MRONJ)
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but real risk for patients on certain bone-affecting medications, especially bisphosphonates (Fosamax, Zometa) and denosumab (Prolia, Xgeva). It happens when jaw bone fails to heal properly after dental trauma like an extraction.
The right move is not to avoid dental care, which often makes things worse by letting infections develop. The right move is to coordinate dental work carefully, with awareness of the medication, timing, and other risk factors. Most patients on these medications can have safe dental care with the right planning.
Any exposed bone in the mouth in a patient on bone-affecting medications is a reason to come in, even when not painful. Early MRONJ responds better to conservative care than advanced cases do.
- Any visible exposed bone in the mouth, even if painless
- A tooth socket that is not healing weeks after extraction
- Persistent jaw pain in the area of a recent dental procedure
- A non-healing sore on the gums that has been present more than two weeks
- Numbness or tingling in the jaw, lip, or chin
- Spreading swelling in the face or jaw
- Fever paired with jaw pain or swelling
- Active drainage from the affected area
- Difficulty swallowing or breathing
| Medication | Typical use | MRONJ risk |
|---|---|---|
| Oral bisphosphonates (alendronate / Fosamax) | Osteoporosis | Low (well under 1 percent) |
| IV bisphosphonates (zoledronic acid / Zometa) | Cancer with bone involvement | Substantially higher (a few percent) |
| Denosumab osteoporosis dose (Prolia) | Osteoporosis | Comparable to oral bisphosphonates |
| Denosumab cancer dose (Xgeva) | Bone metastases, multiple myeloma | Higher than Prolia; comparable to IV bisphosphonates |
| Anti-angiogenic agents (bevacizumab, sunitinib) | Various cancers | Real risk, often combined with bisphosphonates in practice |
Bone is normally a living tissue that constantly remodels itself: cells called osteoclasts break down old bone, and cells called osteoblasts build new bone. Anti-resorptive medications like bisphosphonates and denosumab slow the osteoclast activity dramatically, which is what makes them effective against osteoporosis and bone-metastatic cancer.
The trade-off is that bone healing also slows. The jaw is uniquely vulnerable because it is one of the few bones routinely subjected to invasive procedures (extractions, implant placement, periodontal surgery) and one of the few bones exposed to the outside world through the mouth. When healing fails after a trauma, a section of bone can become necrotic (dies) and stays exposed in the mouth.
The hallmark of MRONJ is exposed jaw bone that has been present for more than eight weeks, with no history of head and neck radiation. It can be painful or painless. It does not heal on its own; treatment is needed.
Risk is concentrated in a few groups:
- Patients on IV bisphosphonates for cancer with bone involvement
- Patients on cancer-dose denosumab (Xgeva)
- Patients on oral bisphosphonates for more than four to five years
- Patients on multiple bone-affecting medications simultaneously (such as a bisphosphonate plus a steroid plus an aromatase inhibitor)
- Patients with poor oral health, diabetes, or smoking on top of any of the above
- Patients undergoing invasive procedures like extractions, especially in the back of the lower jaw
A patient on Fosamax for two years for osteoporosis with no other risk factors is at very low risk. A patient on five years of Fosamax plus Xgeva for cancer with poor oral hygiene is at substantially higher risk. The conversation is always specific to the full picture.
The single most effective intervention is pre-treatment optimization: getting any urgent or hopeless teeth taken care of before starting a bone-affecting medication, when possible. This is standard practice in cancer care now, but is sometimes overlooked when osteoporosis medications are started.
For patients already on the medication, prevention focuses on:
- Meticulous oral hygiene to reduce the bacterial load and the need for invasive procedures
- Regular dental exams every six months at minimum, more often for higher-risk patients
- Addressing any infections or hopeless teeth promptly rather than waiting
- Coordinating any extractions or invasive surgery carefully with the prescribing physician
- Considering atraumatic surgical techniques and prophylactic antibiotics when extractions are needed
Early-stage MRONJ (exposed bone without infection or other complications) is usually managed conservatively. Antimicrobial mouth rinses (chlorhexidine), oral antibiotics if infection is present, and careful local care often allow the area to seal over without surgery.
More advanced MRONJ (infection, pain, larger areas of dead bone) requires more aggressive management. Surgical removal of the necrotic bone is sometimes needed, often by an oral and maxillofacial surgeon. The goal is to remove non-viable tissue and let healthy bone heal around it.
Throughout treatment, coordination with the prescribing physician is part of the plan. A brief drug holiday is sometimes considered for severe cases, balancing the risk of stopping the medication against the difficulty of healing the MRONJ.
It is tempting to think that the safest approach for a patient on Fosamax is to avoid dental work entirely. The opposite is usually true: untreated infections, abscessed teeth, and advanced gum disease cause much more jaw damage than planned dental procedures with proper precautions. A tooth that needs extraction will eventually be extracted, often as an emergency in worse circumstances than a planned extraction with the medication in mind.
The right move is to coordinate dental care actively, not to avoid it.
- Tell your dentist about any bone-affecting medication at the scheduling call, not on the day of the procedure
- Tell us how long you have been on the medication and what dose
- Get any urgent dental work done before starting a new bisphosphonate or denosumab if you have the option
- Maintain meticulous oral hygiene to reduce the chance of needing invasive work
- Watch for any exposed bone or non-healing area in the mouth and report it promptly